Dual & Triple Incretin Deal Benchmarks 2026

Median Upfront

$1.1B

Range: $616M - $1.6B

Total Deal Value

$5.5B

Range: $3.6B - $7.4B

Royalty Rate

17% - 30%

Tiered up to 35%

Dev Milestones

$783M

Range: $530M - $1.0B

Model Your Deal

Market Analysis

Dual and triple incretin agonists represent the next frontier in obesity therapeutics. Tirzepatide (GLP-1/GIP dual agonist) demonstrated category-leading 22.5% weight loss, while retatrutide (GLP-1/GIP/glucagon triple agonist) achieved 24.2% weight loss in Phase 2 — the highest in any obesity trial. These multi-receptor approaches consistently outperform single-receptor GLP-1 agonists.

Phase 2 dual incretin licensing deals command median upfront payments of $1.1B, with total deal values of $5.5B. Triple agonists push even higher at $5.2B total value, reflecting the frontier premium and superior clinical data potential.

The Carmot/Roche acquisition at $2.7B for CT-388 (a GLP-1/GIP/FGF21 triple agonist at Phase 1) demonstrated the massive premium pharma will pay for next-generation multi-receptor approaches. Development milestones average $783M, with commercial milestones reaching $2.6B.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are dual incretin deals worth in 2026?

Phase 2 dual incretin deals average $5.5B total value with $1.1B upfront. Triple incretins command an additional premium at $5.2B total value.

How do dual incretins compare to single GLP-1 agonists?

Dual incretins (GLP-1/GIP) command 10-15% premiums over single GLP-1 agonists, driven by tirzepatide's superior clinical results. The multi-receptor mechanism provides better weight loss efficacy and broader metabolic benefits.

What milestone structures do incretin deals use?

Dual incretin deals allocate heavily toward commercial milestones ($2.6B) given the massive market opportunity. Development milestones ($783M) reflect the clinical de-risking required to demonstrate superiority over existing GLP-1s.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Dual & Triple Incretin Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

GLP-1 Obesity Deal Benchmarks

Metabolic & Obesity Overview

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?